Innate Pharma (IPHYF) Projected to Post Earnings on Wednesday

Key Points

• May 13 earnings: Innate Pharma is expected to report results on Wednesday, May 13, with analysts forecasting EPS of ($0.3524) and revenue of about $5.755 million.
• Shares opened at $1.50, trading at their 52-week high of $1.50 (52-week low $1.37) but remain below the 50-day and 200-day simple moving averages of $1.72 and $1.95, respectively.
• Innate Pharma is a clinical-stage biotech focused on innate immune–based cancer immunotherapies, with lead programs including monalizumab (anti-NKG2A) and lirilumab (anti-KIR).

Innate Pharma (OTCMKTS:IPHYF - Get Free Report) is anticipated to release its resultson Wednesday, May 13th. Analysts expect Innate Pharma to post earnings of ($0.3524) per share and revenue of $5.7550 million for the quarter.

Innate Pharma Stock Performance

Shares of IPHYF opened at $1.50 on Wednesday. Innate Pharma has a 52 week low of $1.37 and a 52 week high of $1.50. The firm's 50-day simple moving average is $1.72 and its 200 day simple moving average is $1.95.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company's pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.